Sofia R. Bartlett
Sofia R. Bartlett
British Columbia Centre for Disease Control, University of British Columbia
Verified email at kirby.unsw.edu.au - Homepage
Title
Cited by
Cited by
Year
The influence of hepatitis C virus genetic region on phylogenetic clustering analysis
FMJ Lamoury, B Jacka, S Bartlett, RA Bull, A Wong, J Amin, J Schinkel, ...
PloS one 10 (7), e0131437, 2015
452015
Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review
SR Bartlett, J Grebely, AA Eltahla, JD Reeves, AYM Howe, V Miller, ...
Hepatology communications 1 (5), 379-390, 2017
362017
Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project
SR Bartlett, P Fox, H Cabatingan, A Jaros, C Gorton, R Lewis, E Priscott, ...
Clinical Infectious Diseases 67 (3), 460-463, 2018
272018
A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies
SR Bartlett, JO Wertheim, RA Bull, GV Matthews, FMJ Lamoury, ...
Journal of viral hepatitis 24 (5), 404-411, 2017
212017
HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection
SR Bartlett, B Jacka, RA Bull, F Luciani, GV Matthews, FMJ Lamoury, ...
Infection, Genetics and Evolution 37, 252-258, 2016
82016
The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals
SR Bartlett, A Yu, N Chapinal, C Rossi, Z Butt, S Wong, M Darvishian, ...
Liver International 39 (12), 2261-2272, 2019
42019
Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE Study
M Martinello, J Yee, SR Bartlett, P Read, D Baker, JJ Post, R Finlayson, ...
Clinical Infectious Diseases, 2019
42019
Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia
M Martinello, S Bartlett, G Dore, R Bopage, R Finlayson, D Baker, M Bloch, ...
Journal of Hepatology 68, S312-S313, 2018
32018
Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types
FMJ Lamoury, S Bartlett, B Jacka, B Hajarizadeh, J Grebely, GV Matthews, ...
The Journal of molecular diagnostics 17 (5), 583-589, 2015
32015
Identification of critical residues in the bifunctional phosphoenolpyruvate synthetase kinase/phosphotransferase of Escherichia coli
S Bartlett, J Seeliger, JN Burnell
Current Topics in Biochemical Research 14, 77-83, 2012
32012
Real-world effectiveness of sofosbuvir/velpatasvir for treatment of chronic hepatitis C in British Columbia, Canada: A population-based cohort study
J Wilton, S Wong, A Yu, A Ramji, D Cook, ZA Butt, M Alvarez, M Binka, ...
Open forum infectious diseases 7 (3), ofaa055, 2020
22020
Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre‐and post‐universal access to direct‐acting antiviral treatment in …
S Bajis, J Grebely, B Hajarizadeh, T Applegate, AD Marshall, ...
Journal of Viral Hepatitis 27 (3), 281-293, 2020
22020
Loss to follow‐up: a significant barrier in the treatment cascade with direct‐acting therapies
M Darvishian, S Wong, M Binka, A Yu, A Ramji, EM Yoshida, J Wong, ...
Journal of Viral Hepatitis 27 (3), 243-260, 2020
22020
Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations
C Rossi, D Jeong, S Wong, G McKee, ZA Butt, J Buxton, J Wong, ...
Journal of hepatology 71 (6), 1116-1125, 2019
22019
A latent class approach to identify multi‐risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015
SR Bartlett, TL Applegate, BP Jacka, M Martinello, FMJ Lamoury, M Danta, ...
Journal of the International AIDS Society 22 (2), e25222, 2019
12019
HEPATITIS C VIRUS REINFECTION AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRAL THERAPY AMONG MSM
N Janjua, S Wong, S Bartlett, P Adu, ZA Butt, J Wong, M Pearce, A Yu, ...
HEPATOLOGY 70, 961A-962A, 2019
2019
REAL-WORLD EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR AS A HEPATITIS C VIRUS INFECTION SALVAGE TREATMENT
M Krajden, D Cook, S Wong, J Wilton, ZA Butt, S Bartlett, M Pearce, ...
HEPATOLOGY 70, 914A-914A, 2019
2019
HEPATITIS C VIRUS REINFECTION AFTER SUCCESSFUL TREATMENT WITH DIRECT ACTING ANTIVIRAL THERAPY IN CANADA
N Janjua, S Wong, S Bartlett, ZA Butt, J Wong, P Adu, H Samji, A Yu, ...
HEPATOLOGY 70, 183A-183A, 2019
2019
FACTORS ASSOCIATED WITH HCV TREATMENT INITIATION ACROSS ETHNIC GROUPS IN BRITISH COLUMBIA, CANADA: A POPULATION-BASED COHORT STUDY
M Pearce, H Samji, S Bartlett, S Wong, A Yu, M Binka, MJ Alvarez, ZA Butt, ...
HEPATOLOGY 70, 345A-346A, 2019
2019
P388 Evolution of hepatitis C care cascades among HIV and hepatitis B co-infected patients in british columbia, canada
G Mckee, N Chapinal, Z Butt, C Rossi, S Wong, M Gilbert, J Wong, ...
Sexually Transmitted Infections 95 (Suppl 1), A191-A191, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–20